Department of Ophthalmology, Tabriz University (Medical Sciences), Tabriz, Iran.
Ren Fail. 2012;34(9):1123-8. doi: 10.3109/0886022X.2012.717479. Epub 2012 Sep 6.
Patients on maintenance hemodialysis (HD) face an increased risk of atherosclerosis, a crucial problem and the leading cause of cardiovascular morbidity and mortality. This study was designed to evaluate the effects of zinc supplementation on paraoxonase (PON) enzyme activity in patients on HD.
This double-blind randomized controlled trial was conducted from June 2005 to June 2007. Sixty HD patients were enrolled and divided into two groups: treatment (case) and control. The treatment and control groups were treated with 100 mg/day zinc or placebo, respectively, for 2 months. Serum zinc concentration was measured by atomic absorption spectrophotometry. PON activity was evaluated by spectrophotometric method. Lipid profile was determined using commercial kits, and apolipoprotein AI (Apo-AI) and B (Apo-B) levels were measured by commercial immunoturbidimetric kits.
In the case group, there was no significant change in the serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), and Apo-B levels, while the serum levels of high-density lipoprotein (HDL), Apo-AI, and PON activity were significantly increased (p = 0.02). In the control group, although significant increases were observed in the serum levels of TC, TG, and Apo-B (p = 0.009, 0.019, and 0.001, respectively), the serum PON activity was significantly decreased (p = 0.025) and the serum levels of HDL, LDL, and Apo-AI were not changed. At the end of intervention period, the serum level of Apo-AI and PON activity were significantly higher in the case group.
Zinc supplementation increased both the activity of PON and the serum level of Apo-AI in the HD patients.
维持性血液透析（HD）患者面临动脉粥样硬化风险增加，这是一个关键问题，也是心血管发病率和死亡率的主要原因。本研究旨在评估锌补充对 HD 患者对氧磷酶（PON）酶活性的影响。
这是一项双盲随机对照试验，于 2005 年 6 月至 2007 年 6 月进行。纳入 60 名 HD 患者，分为治疗（病例）组和对照组。治疗组和对照组分别接受 100mg/天锌或安慰剂治疗，为期 2 个月。血清锌浓度采用原子吸收分光光度法测定。PON 活性采用分光光度法评估。血脂谱采用商业试剂盒测定，载脂蛋白 AI（Apo-AI）和 B（Apo-B）水平采用商业免疫比浊试剂盒测定。
病例组血清总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白（LDL）和 Apo-B 水平无显著变化，而高密度脂蛋白（HDL）、Apo-AI 和 PON 活性血清水平显著升高（p=0.02）。对照组 TC、TG 和 Apo-B 血清水平显著升高（p=0.009、0.019 和 0.001），而 PON 活性血清水平显著降低（p=0.025），HDL、LDL 和 Apo-AI 血清水平无变化。干预期末，病例组血清 Apo-AI 和 PON 活性水平显著升高。
锌补充可提高 HD 患者 PON 活性和血清 Apo-AI 水平。
